New York City health officials have declared an end to the city’s biggest measles outbreak in nearly 3 decades; Senator Bernie Sanders, I-Vermont, has proposed canceling $81 billion in existing medical debt; Vertex Pharmaceuticals is taking a chance on a start-up’s early-stage science that could potentially one day emerge as a functional cure for type 1 diabetes (T1D).
Health officials in New York City on Tuesday declared an end to the city’s biggest measles outbreak in nearly 3 decades and rescinded an emergency order requiring people in parts of Brooklyn to be vaccinated. Mayor Bill de Blasio credited the end of the outbreak to the work of community organizations and Jewish leaders, who “helped encourage vaccinations and achieve record immunization levels in parts of Brooklyn.” Since the emergency order was issued in April, more than 15,500 people have received the measles vaccine, reported The Hill.
Senator Bernie Sanders, I-Vermont, has proposed canceling over $80 billion in existing medical debt for Americans. In a statement, Sanders said that the government would negotiate and pay off past-due medical bills that have been reported to credit agencies and that the proposal would repeal some elements of the 2005 bankruptcy reform bill, as well as allow other existing and future medical debt to be cleared. However, the presidential hopeful offered no details on how the plan would be financed, according to Reuters.
Vertex Pharmaceuticals has announced plans to acquire Semma Therapeutics for $950 million, taking a chance on the start-up’s early-stage science that could potentially one day emerge as a functional cure for type 1 diabetes (T1D). Based on the work of a Harvard University stem cell scientist, Semma Therapeutics uses an approach that turns moldable stem cells into beta cells, which produce insulin and are mistakenly attacked by the immune system in T1D. According to STAT News, if the approach works and the lab-grown beta cells replace those lost to T1D, the cells would be transplanted directly into the liver or meted out by an implant.
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Team-Based CINEMA Program Targets SDOH and Precision Care in Diabetes
December 20th 2024Ian Neeland, MD, discusses the CINEMA program's impact on addressing social determinants of health (SDOH) in Ohio and the importance of precision risk tests to reduce cardiovascular metabolic disease risk.
Read More